SLC5A2 and diabetic ketoacidosis: Some studies demonstrate that starting SGLT2 inhibitors may result in longer hospitalizations for complications such as diabetic ketoacidosis or low fluid levels, especially in elderly or frail patients (Zelnick et al., 2021; Fralick et al., 2017).